154 related articles for article (PubMed ID: 25075102)
1. A novel assay system for macrophage-activating factor activity using a human U937 cell line.
Ishikawa M; Inoue T; Inui T; Kuchiike D; Kubo K; Uto Y; Nishikata T
Anticancer Res; 2014 Aug; 34(8):4577-81. PubMed ID: 25075102
[TBL] [Abstract][Full Text] [Related]
2. Degalactosylated/desialylated human serum containing GcMAF induces macrophage phagocytic activity and in vivo antitumor activity.
Kuchiike D; Uto Y; Mukai H; Ishiyama N; Abe C; Tanaka D; Kawai T; Kubo K; Mette M; Inui T; Endo Y; Hori H
Anticancer Res; 2013 Jul; 33(7):2881-5. PubMed ID: 23780974
[TBL] [Abstract][Full Text] [Related]
3. Preparation of Gc protein-derived macrophage activating factor (GcMAF) and its structural characterization and biological activities.
Mohamad SB; Nagasawa H; Uto Y; Hori H
Anticancer Res; 2002; 22(6C):4297-300. PubMed ID: 12553073
[TBL] [Abstract][Full Text] [Related]
4. Effect of the Gc-derived macrophage-activating factor precursor (preGcMAF) on phagocytic activation of mouse peritoneal macrophages.
Uto Y; Yamamoto S; Takeuchi R; Nakagawa Y; Hirota K; Terada H; Onizuka S; Nakata E; Hori H
Anticancer Res; 2011 Jul; 31(7):2489-92. PubMed ID: 21873164
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a Macrophage-activating Factor Assay System Using the Human Monocytic Cell Line THP-1.
Inoue T; Ishikawa M; Sumiya Y; Kohda H; Inui T; Kuchiike D; Kubo K; Uto Y; Nishikata T
Anticancer Res; 2015 Aug; 35(8):4441-5. PubMed ID: 26168484
[TBL] [Abstract][Full Text] [Related]
6. Gc protein-derived macrophage activating factor (GcMAF): isoelectric focusing pattern and tumoricidal activity.
Mohamad SB; Nagasawa H; Sasaki H; Uto Y; Nakagawa Y; Kawashima K; Hori H
Anticancer Res; 2003; 23(6a):4451-7. PubMed ID: 14666733
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).
Yamamoto N; Suyama H; Yamamoto N; Ushijima N
Int J Cancer; 2008 Jan; 122(2):461-7. PubMed ID: 17935130
[TBL] [Abstract][Full Text] [Related]
8. Phagocytic Activation of Macrophages with Serum MAF Depends on Engulfment Efficiency and Not Migratory Activity.
Mashiba R; Ishikawa M; Sumiya YU; Kawakatsu K; Tran NK; Nishikata T
Anticancer Res; 2018 Jul; 38(7):4295-4298. PubMed ID: 29970564
[TBL] [Abstract][Full Text] [Related]
9. Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors.
Sumiya YU; Inoue T; Ishikawa M; Inui T; Kuchiike D; Kubo K; Uto Y; Nishikata T
Anticancer Res; 2016 Jul; 36(7):3619-23. PubMed ID: 27354632
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor.
Yamamoto N; Naraparaju VR
Cancer Res; 1997 Jun; 57(11):2187-92. PubMed ID: 9187119
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D binding protein-macrophage activating factor inhibits HCC in SCID mice.
Nonaka K; Onizuka S; Ishibashi H; Uto Y; Hori H; Nakayama T; Matsuura N; Kanematsu T; Fujioka H
J Surg Res; 2012 Jan; 172(1):116-22. PubMed ID: 20855083
[TBL] [Abstract][Full Text] [Related]
12. Macrophage Activation Mechanisms in Human Monocytic Cell Line-derived Macrophages.
Sumiya Y; Ishikawa M; Inoue T; Inui T; Kuchiike D; Kubo K; Uto Y; Nishikata T
Anticancer Res; 2015 Aug; 35(8):4447-51. PubMed ID: 26168485
[TBL] [Abstract][Full Text] [Related]
13. β-Galactosidase treatment is a common first-stage modification of the three major subtypes of Gc protein to GcMAF.
Uto Y; Yamamoto S; Mukai H; Ishiyama N; Takeuchi R; Nakagawa Y; Hirota K; Terada H; Onizuka S; Hori H
Anticancer Res; 2012 Jun; 32(6):2359-64. PubMed ID: 22641675
[TBL] [Abstract][Full Text] [Related]
14. Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis.
Inui T; Katsuura G; Kubo K; Kuchiike D; Chenery L; Uto Y; Nishikata T; Mette M
Anticancer Res; 2016 Jul; 36(7):3771-4. PubMed ID: 27354653
[TBL] [Abstract][Full Text] [Related]
15. Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports.
Inui T; Kubo K; Kuchiike D; Uto Y; Nishikata T; Sakamoto N; Mette M
Anticancer Res; 2015 Aug; 35(8):4545-9. PubMed ID: 26168499
[TBL] [Abstract][Full Text] [Related]
16. Gc-protein-derived macrophage activating factor counteracts the neuronal damage induced by oxaliplatin.
Morucci G; Branca JJ; Gulisano M; Ruggiero M; Paternostro F; Pacini A; Di Cesare Mannelli L; Pacini S
Anticancer Drugs; 2015 Feb; 26(2):197-209. PubMed ID: 25304987
[TBL] [Abstract][Full Text] [Related]
17. A designed glycoprotein analogue of Gc-MAF exhibits native-like phagocytic activity.
Bogani F; McConnell E; Joshi L; Chang Y; Ghirlanda G
J Am Chem Soc; 2006 Jun; 128(22):7142-3. PubMed ID: 16734450
[TBL] [Abstract][Full Text] [Related]
18. Effects of oxaliplatin and oleic acid Gc-protein-derived macrophage-activating factor on murine and human microglia.
Branca JJ; Morucci G; Malentacchi F; Gelmini S; Ruggiero M; Pacini S
J Neurosci Res; 2015 Sep; 93(9):1364-77. PubMed ID: 25782915
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.
Yamamoto N; Suyama H; Nakazato H; Yamamoto N; Koga Y
Cancer Immunol Immunother; 2008 Jul; 57(7):1007-16. PubMed ID: 18058096
[TBL] [Abstract][Full Text] [Related]
20. Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity.
Nagasawa H; Uto Y; Sasaki H; Okamura N; Murakami A; Kubo S; Kirk KL; Hori H
Anticancer Res; 2005; 25(6A):3689-95. PubMed ID: 16302727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
